These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 31774221)

  • 1. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions.
    Monds LA; Bravo M; Mills L; Malcolm A; Gilliver R; Wood W; Harrod ME; Read P; Nielsen S; Dietze PM; Lenton S; Bleeker AM; Lintzeris N
    Drug Alcohol Rev; 2022 Jul; 41(5):1085-1094. PubMed ID: 35442514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
    Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
    Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program.
    Chronister KJ; Lintzeris N; Jackson A; Ivan M; Dietze PM; Lenton S; Kearley J; van Beek I
    Drug Alcohol Rev; 2018 May; 37(4):464-471. PubMed ID: 27071354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities.
    Dietze PM; Stare M; Cogger S; Nambiar D; Olsen A; Burns L; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):457-463. PubMed ID: 29744979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of take-home naloxone programs in Australia.
    Dwyer R; Olsen A; Fowlie C; Gough C; van Beek I; Jauncey M; Lintzeris N; Oh G; Dicka J; Fry CL; Hayllar J; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):440-449. PubMed ID: 29744980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use.
    Curtis M; Dietze P; Aitken C; Kirwan A; Kinner SA; Butler T; Stoové M
    Harm Reduct J; 2018 Sep; 15(1):48. PubMed ID: 30241532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.
    Holmén E; Warnqvist A; Kåberg M
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):24. PubMed ID: 37087485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs.
    Dietze PM; Draper B; Olsen A; Chronister KJ; van Beek I; Lintzeris N; Dwyer R; Nelson M; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):472-479. PubMed ID: 29473245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
    Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
    JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a randomised controlled trial of take home naloxone distributed in emergency settings likely to be feasible and acceptable? Findings from a UK qualitative study exploring perspectives of people who use opioids and emergency services staff.
    Sampson FC; Hughes J; Long J; Buykx P; Goodacre SW; Snooks H; Edwards A; Evans B; Jones J; Moore C; Johnston S
    BMC Emerg Med; 2024 Apr; 24(1):75. PubMed ID: 38679713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes.
    Williams AV; Marsden J; Strang J
    Addiction; 2014 Feb; 109(2):250-9. PubMed ID: 24103087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis.
    McAuley A; Bouttell J; Barnsdale L; Mackay D; Lewsey J; Hunter C; Robinson M
    Addiction; 2017 Feb; 112(2):301-308. PubMed ID: 27614084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.